Shanghai Pharmaceuticals Holding Co., Ltd (2607.HK)
2607.HK Stock Price Chart
Explore Shanghai Pharmaceuticals Holding Co., Ltd interactive price chart. Choose custom timeframes to analyze 2607.HK price movements and trends.
2607.HK Company Profile
Discover essential business fundamentals and corporate details for Shanghai Pharmaceuticals Holding Co., Ltd (2607.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Distribution
IPO Date
20 May 2011
Employees
49.40K
Website
https://www.sphchina.comCEO
Qiuhua Yang
Description
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
2607.HK Financial Timeline
Browse a chronological timeline of Shanghai Pharmaceuticals Holding Co., Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 30 Oct 2025
Revenue estimate is $73.93B.
Earnings released on 28 Aug 2025
EPS came in at $0.91 matching the estimated $0.91.
Dividend declared on 16 Jul 2025
A dividend of $0.32 per share was announced, adjusted to $0.32. The dividend was paid on 25 Aug 2025.
Earnings released on 24 Apr 2025
EPS came in at $0.38 falling short of the estimated $0.45 by -14.30%, while revenue for the quarter reached $75.51B , beating expectations by +2.16%.
Earnings released on 26 Mar 2025
EPS came in at $0.15 falling short of the estimated $0.25 by -40.04%, while revenue for the quarter reached $69.81B , missing expectations by -8.65%.
Earnings released on 29 Oct 2024
EPS came in at $0.30 surpassing the estimated $0.27 by +11.11%, while revenue for the quarter reached $77.70B , beating expectations by +8.78%.
Earnings released on 26 Aug 2024
EPS came in at $0.37 surpassing the estimated $0.33 by +12.12%, while revenue for the quarter reached $74.38B , missing expectations by -6.20%.
Earnings released on 26 Apr 2024
EPS came in at $0.42 falling short of the estimated $0.55 by -23.64%, while revenue for the quarter reached $75.90B , missing expectations by -0.16%.
Earnings released on 29 Mar 2024
EPS came in at -$0.01 falling short of the estimated $0.43 by -102.33%, while revenue for the quarter reached $69.49B , beating expectations by +0.51%.
Earnings released on 27 Oct 2023
EPS came in at $0.32 falling short of the estimated $0.41 by -21.95%, while revenue for the quarter reached $69.63B , missing expectations by -7.88%.
Earnings released on 29 Aug 2023
EPS came in at $0.72 surpassing the estimated $0.55 by +30.91%, while revenue for the quarter reached $71.77B , beating expectations by +2.73%.
Earnings released on 31 Mar 2023
EPS came in at $0.47 surpassing the estimated -$0.33 by +242.56%, while revenue for the quarter reached $75.60B , beating expectations by +8.03%.
Earnings released on 31 Dec 2022
EPS came in at $0.26 falling short of the estimated $0.46 by -43.36%, while revenue for the quarter reached $65.34B , missing expectations by -4.79%.
Earnings released on 30 Sept 2022
EPS came in at $0.43 surpassing the estimated $0.43 by +0.39%, while revenue for the quarter reached $69.10B , beating expectations by +7.51%.
Earnings released on 30 Jun 2022
EPS came in at $1.01 surpassing the estimated $0.53 by +91.65%, while revenue for the quarter reached $64.16B , missing expectations by -3.73%.
Earnings released on 31 Mar 2022
EPS came in at $0.54 surpassing the estimated $0.48 by +13.99%, while revenue for the quarter reached $70.12B , beating expectations by +3.51%.
Earnings released on 31 Dec 2021
EPS came in at $0.26 , while revenue for the quarter reached $67.16B .
Earnings released on 30 Sept 2021
EPS came in at $0.39 falling short of the estimated $0.48 by -18.32%, while revenue for the quarter reached $67.22B , beating expectations by +1.33%.
Earnings released on 30 Jun 2021
EPS came in at $0.62 , while revenue for the quarter reached $64.40B .
Earnings released on 31 Mar 2021
EPS came in at $0.89 , while revenue for the quarter reached $61.10B .
Earnings released on 31 Dec 2020
EPS came in at $0.38 , while revenue for the quarter reached $61.27B .
Earnings released on 30 Sept 2020
EPS came in at $0.47 , while revenue for the quarter reached $60.61B .
2607.HK Stock Performance
Access detailed 2607.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.